Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Crispr Therapeutics Ag
(NQ:
CRSP
)
55.14
+3.52 (+6.82%)
Streaming Delayed Price
Updated: 3:37 PM EST, Nov 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crispr Therapeutics Ag
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
November 08, 2024
The rock star fund investor made a lot of big moves on Thursday.
Via
The Motley Fool
Smaller Cap Biotechs Are In Season: How Are We Doing?
November 07, 2024
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
Via
Talk Markets
3 Companies Building Tomorrow's Game-Changing Technologies
November 05, 2024
These pioneering companies are transforming delivery, medicine, and space access--potentially creating massive opportunities for early investors.
Via
The Motley Fool
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
November 02, 2024
It won't be able to be profitable without hitting its targets for both of these figures.
Via
The Motley Fool
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
October 31, 2024
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.
Via
Benzinga
Topics
ETFs
Stocks
Exposures
US Equities
12 High-Growth Stocks That Could Deliver Parabolic Returns
October 28, 2024
These 12 innovative companies could deliver exponential returns over the next quarter century.
Via
The Motley Fool
The Ultimate Biotech Stock to Buy With $50 Right Now
October 26, 2024
This company might be worth far more than many realize.
Via
The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
October 22, 2024
The aggressive growth icon kicked off the new trading week by buying some of her favorite stocks.
Via
The Motley Fool
Why We Buy Stocks
October 21, 2024
Is fear of missing out (FOMO) controlling your portfolio?
Via
The Motley Fool
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
October 19, 2024
Yes, bargains can still be found in the stock market.
Via
The Motley Fool
Why I Keep Buying These 14 Incredible Growth Stocks
October 16, 2024
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is CRISPR Therapeutics Stock a Buy?
October 13, 2024
The markets this biotech is looking to enter could be extremely lucrative.
Via
The Motley Fool
2 Biotech Stocks That Are Screaming Buys This Month
October 12, 2024
They won't remain southbound forever.
Via
The Motley Fool
This Healthcare Growth Stock Could Be a Steal of a Deal Right Now
October 05, 2024
CRISPR Therapeutics is trading around multiyear lows.
Via
The Motley Fool
These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer
October 02, 2024
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
Via
The Motley Fool
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
September 26, 2024
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.
Via
Investor's Business Daily
3 Dirt Cheap Stocks to Buy Right Now
September 21, 2024
Bargain hunters should love these great stocks.
Via
The Motley Fool
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
September 19, 2024
There's a lot of growth on the way, and soon.
Via
The Motley Fool
1 Biotech Stock Down 62% to Buy and Hold
September 12, 2024
It's an excellent opportunity to buy shares of what could become a biotech giant on the dip.
Via
The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
September 12, 2024
An investment in these players today could score a big win down the road.
Via
The Motley Fool
Looking for Stock Bargains With Room to Run? Try This.
September 11, 2024
Investing tips from Bill Mann, The Motley Fool's director of small-cap research.
Via
The Motley Fool
Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?
September 05, 2024
Is the potential upside for CRISPR Therapeutics too massive to ignore?
Via
The Motley Fool
3 Monster Biotech Stocks to Buy Before 2025
September 02, 2024
These companies are nearly in the sweet spot of risk versus reward in biotech.
Via
The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
August 26, 2024
The companies are chasing major innovations.
Via
The Motley Fool
Got the Market Sell-Off Blues? Do These 3 Things Right Now
August 11, 2024
You aren't powerless in the face of what the market throws at you.
Via
The Motley Fool
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
August 08, 2024
The "Mad Money" host says Dexcom had "a real bad miss... they still really haven't fully explained why that is."
Via
Benzinga
7 Biotech Stocks to Buy for Their Game-Changing Potential
August 08, 2024
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.
Via
InvestorPlace
The 3 Best Gene Editing Stocks to Buy in August 2024
August 07, 2024
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.
Via
InvestorPlace
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
August 06, 2024
Shares of the rare disease drugmaker are already up more than 40% over the past year.
Via
The Motley Fool
CRSP Stock Earnings: CRISPR Therapeutics Beats EPS, Misses Revenue for Q2 2024
August 05, 2024
CRSP stock results show that CRISPR Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.